

Bernard J Gersh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/289808/publications.pdf>

Version: 2024-02-01

401
papers

46,525
citations

4370

86
h-index

1851

209
g-index

425
all docs

425
docs citations

425
times ranked

34215
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992. | 13.9 | 7,537 |
| 2 | 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477. | 1.0 | 4,210 |
| 3 | Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. <i>Circulation</i> , 2006, 114, 119-125. | 1.6 | 2,292 |
| 4 | Bivalirudin during Primary PCI in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2218-2230. | 13.9 | 1,693 |
| 5 | Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. <i>American Journal of Cardiology</i> , 2002, 90, 1284-1289. | 0.7 | 998 |
| 6 | 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011, 58, e212-e260. | 1.2 | 984 |
| 7 | The Natural History of Lone Atrial Fibrillation. <i>New England Journal of Medicine</i> , 1987, 317, 669-674. | 13.9 | 906 |
| 8 | An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. <i>Lancet, The</i> , 2019, 394, 861-867. | 6.3 | 794 |
| 9 | Controversies in ventricular remodelling. <i>Lancet, The</i> , 2006, 367, 356-367. | 6.3 | 742 |
| 10 | 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. <i>Circulation</i> , 2011, 124, 2761-2796. | 1.6 | 725 |
| 11 | Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 470-476. | 1.2 | 677 |
| 12 | Prediction of Cardiovascular Outcomes With Left Atrial Size. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1018-1023. | 1.2 | 677 |
| 13 | Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 1946-1959. | 13.9 | 657 |
| 14 | Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , 2014, 383, 1933-1943. | 6.3 | 589 |
| 15 | Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1636-1644. | 1.2 | 575 |
| 16 | Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. <i>Mayo Clinic Proceedings</i> , 2001, 76, 467-475. | 1.4 | 530 |
| 17 | Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. <i>European Heart Journal</i> , 2009, 30, 1038-1045. | 1.0 | 485 |
| 18 | Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867. | 1.6 | 453 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1397-1405. | 1.2 | 451 |
| 20 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet</i> , The, 2011, 377, 2193-2204. | 6.3 | 421 |
| 21 | Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 1709-1716. | 1.0 | 411 |
| 22 | Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2597-2604. | 1.2 | 401 |
| 23 | Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2779-2790. | 1.2 | 398 |
| 24 | Mortality Trends in Patients Diagnosed With First Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2007, 49, 986-992. | 1.2 | 394 |
| 25 | Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 979. | 3.8 | 393 |
| 26 | Mitral Valve Operation in Postinfarction Rupture of a Papillary Muscle: Immediate Results and Long-Term Follow-Up of 22 Patients. <i>Mayo Clinic Proceedings</i> , 1992, 67, 1023-1030. | 1.4 | 391 |
| 27 | Novel therapeutic concepts * The epidemic of cardiovascular disease in the developing world: global implications. <i>European Heart Journal</i> , 2010, 31, 642-648. | 1.0 | 366 |
| 28 | Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1199-1205. | 1.2 | 353 |
| 29 | Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation. <i>Circulation</i> , 2007, 115, 3050-3056. | 1.6 | 347 |
| 30 | Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, . | 1.6 | 341 |
| 31 | Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, 729-736. | 1.6 | 299 |
| 32 | Cell therapy for cardiac repair—lessons from clinical trials. <i>Nature Reviews Cardiology</i> , 2014, 11, 232-246. | 6.1 | 261 |
| 33 | 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2703-2738. | 1.2 | 252 |
| 34 | Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2008, 118, 131-139. | 1.6 | 251 |
| 35 | Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2012, 126, 2374-2380. | 1.6 | 243 |
| 36 | Prognostic Impact of Staged Versus One-Time Multivessel Percutaneous Intervention in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 704-711. | 1.2 | 236 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, e153-e193. | 0.4 | 236 |
| 38 | Reappraisal of Ischemic Heart Disease. <i>Circulation</i> , 2018, 138, 1463-1480. | 1.6 | 230 |
| 39 | Time to Presentation With Acute Myocardial Infarction in the Elderly. <i>Circulation</i> , 2000, 102, 1651-1656. | 1.6 | 225 |
| 40 | Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 488-494. | 1.6 | 224 |
| 41 | The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota. <i>Journal of the American College of Cardiology</i> , 2003, 42, 93-100. | 1.2 | 217 |
| 42 | Left Atrial Reservoir Function as a Potent Marker for First Atrial Fibrillation or Flutter in Persons ≥65 Years of Age. <i>American Journal of Cardiology</i> , 2008, 101, 1626-1629. | 0.7 | 213 |
| 43 | Left Atrial Mechanics: Echocardiographic Assessment and Clinical Implications. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 463-478. | 1.2 | 207 |
| 44 | The case for surgery in obstructive hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2044-2053. | 1.2 | 204 |
| 45 | Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2015, 132, 624-632. | 1.6 | 203 |
| 46 | Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2015, 169, 647-654.e2. | 1.2 | 202 |
| 47 | Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High-Risk Population. <i>Journal of the American Heart Association</i> , 2014, 3, e001002. | 1.6 | 200 |
| 48 | Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population. <i>JAMA Cardiology</i> , 2017, 2, 1120. | 3.0 | 200 |
| 49 | Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2007, 49, 350-357. | 1.2 | 199 |
| 50 | Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2621-2632. | 1.2 | 198 |
| 51 | Reperfusion Injury, Microvascular Dysfunction, and Cardioprotection. <i>Circulation</i> , 2009, 120, 2105-2112. | 1.6 | 192 |
| 52 | N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284. | 1.2 | 191 |
| 53 | Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. <i>Journal of the American College of Cardiology</i> , 2020, 75, 722-733. | 1.2 | 183 |
| 54 | Coronary Artery Disease in Patients ≥80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2015-2040. | 1.2 | 175 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. <i>European Heart Journal</i> , 2005, 26, 667-674. | 1.0 | 173 |
| 56 | Hypertrophic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2018, 6, 364-375. | 1.9 | 173 |
| 57 | Left Atrial Volume Predicts the Risk of Atrial Fibrillation After Cardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2006, 48, 779-786. | 1.2 | 166 |
| 58 | Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1781-1791. | 1.2 | 156 |
| 59 | Prognostic Value of Treadmill Exercise Testing. <i>Circulation</i> , 1998, 98, 2836-2841. | 1.6 | 155 |
| 60 | Unrecognized Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2001, 135, 801. | 2.0 | 155 |
| 61 | Risks for atrial fibrillation and congestive heart failure in patients ≥ 65 years of age with abnormal left ventricular diastolic relaxation. <i>American Journal of Cardiology</i> , 2004, 93, 54-58. | 0.7 | 154 |
| 62 | Cardiopietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw543. | 1.0 | 148 |
| 63 | Women with hypertrophic cardiomyopathy have worse survival. <i>European Heart Journal</i> , 2017, 38, 3434-3440. | 1.0 | 147 |
| 64 | Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. <i>American Heart Journal</i> , 2011, 162, 606-612.e1. | 1.2 | 137 |
| 65 | Cardiac Cell Repair Therapy: A Clinical Perspective. <i>Mayo Clinic Proceedings</i> , 2009, 84, 876-892. | 1.4 | 134 |
| 66 | High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61. | 1.2 | 133 |
| 67 | Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. <i>The Lancet Digital Health</i> , 2020, 2, e486-e488. | 5.9 | 128 |
| 68 | Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99. | 1.2 | 126 |
| 69 | Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes. <i>Circulation</i> , 2012, 125, 2613-2620. | 1.6 | 125 |
| 70 | Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1325-1335. | 1.2 | 124 |
| 71 | Revascularization in Severe Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 567-574. | 1.2 | 123 |
| 72 | Relation of Arterial Stiffness to Left Ventricular Diastolic Function and Cardiovascular Risk Prediction in Patients ≥ 65 Years of Age. <i>American Journal of Cardiology</i> , 2006, 98, 1387-1392. | 0.7 | 123 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. <i>Heart Rhythm</i> , 2016, 13, 1418-1424. | 0.3 | 123 |
| 74 | Surgery Insight: septal myectomy for obstructive hypertrophic cardiomyopathy—the Mayo Clinic experience. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 503-512. | 3.3 | 120 |
| 75 | Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 167, 735-742.e2. | 1.2 | 120 |
| 76 | Impact of Left Atrial Appendage Closure During Cardiac Surgery on the Occurrence of Early Postoperative Atrial Fibrillation, Stroke, and Mortality. <i>Circulation</i> , 2017, 135, 366-378. | 1.6 | 119 |
| 77 | Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2116. | 3.8 | 114 |
| 78 | Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006930. | 1.4 | 106 |
| 79 | Atrial fibrillation ablation in practice: assessing CABANA generalizability. <i>European Heart Journal</i> , 2019, 40, 1257-1264. | 1.0 | 105 |
| 80 | Utility of Left Bundle Branch Block as a Diagnostic Criterion for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2011, 107, 1111-1116. | 0.7 | 101 |
| 81 | Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000. <i>Stroke</i> , 2005, 36, 2362-2366. | 1.0 | 98 |
| 82 | Burden of Arrhythmia in Pregnancy. <i>Circulation</i> , 2017, 135, 619-621. | 1.6 | 97 |
| 83 | Epidemiological Profile of Atrial Fibrillation: A Contemporary Perspective. <i>Progress in Cardiovascular Diseases</i> , 2005, 48, 1-8. | 1.6 | 94 |
| 84 | New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 739-748. | 1.2 | 94 |
| 85 | Complete Versus Incomplete Revascularization With Coronary Artery Bypass Graft or Percutaneous Intervention in Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 597-604. | 1.4 | 91 |
| 86 | Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2017, 5, 44-52. | 1.9 | 91 |
| 87 | Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014. <i>Circulation: Heart Failure</i> , 2019, 12, e005929. | 1.6 | 91 |
| 88 | Methods of Coronary Revascularization — Things May Not Be as They Seem. <i>New England Journal of Medicine</i> , 2005, 352, 2235-2237. | 13.9 | 89 |
| 89 | Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , 2017, 19, 1520-1529. | 2.9 | 89 |
| 90 | Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2018, 131, 269-275.e2. | 0.6 | 87 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Utilization of Palliative Care for Cardiogenic Shock Complicating Acute Myocardial Infarction: A 15-Year National Perspective on Trends, Disparities, Predictors, and Outcomes. <i>Journal of the American Heart Association</i> , 2019, 8, e011954. | 1.6 | 83 |
| 92 | Cardiac involvement in the long-term implications of COVID-19. <i>Nature Reviews Cardiology</i> , 2022, 19, 332-341. | 6.1 | 83 |
| 93 | High Prevalence of Occult Heart Failure With Preserved Ejection Fraction Among Patients With Atrial Fibrillation and Dyspnea. <i>Circulation</i> , 2018, 137, 534-535. | 1.6 | 82 |
| 94 | Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. <i>Nature Reviews Cardiology</i> , 2021, 18, 155-168. | 6.1 | 81 |
| 95 | Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019, 42, 568-571. | 0.7 | 80 |
| 96 | Left Ventricular Post-Infarct Remodeling. <i>JACC: Heart Failure</i> , 2020, 8, 131-140. | 1.9 | 80 |
| 97 | Mechanical and Electrical Complications of Acute Myocardial Infarction. <i>Mayo Clinic Proceedings</i> , 1990, 65, 709-730. | 1.4 | 78 |
| 98 | International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2466-2476. | 1.2 | 78 |
| 99 | Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. <i>European Journal of Heart Failure</i> , 2016, 18, 160-168. | 2.9 | 77 |
| 100 | Association of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54. | 3.0 | 77 |
| 101 | Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort. <i>Circulation</i> , 2020, 141, 454-463. | 1.6 | 77 |
| 102 | Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2691-2698. | 1.2 | 76 |
| 103 | Cell therapy for human ischemic heart diseases: Critical review and summary of the clinical experiences. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 75, 12-24. | 0.9 | 75 |
| 104 | Long-term Outcome of Women Compared With Men After Successful Coronary Angioplasty. <i>Circulation</i> , 1995, 91, 2876-2881. | 1.6 | 72 |
| 105 | Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. <i>Annals of Intensive Care</i> , 2019, 9, 96. | 2.2 | 71 |
| 106 | Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young. <i>Circulation: Heart Failure</i> , 2020, 13, e007154. | 1.6 | 71 |
| 107 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 772-791. | 0.4 | 69 |
| 108 | Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017, 3, 192-197. | 1.8 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2019, 123, 489-497. | 0.7 | 69 |
| 110 | Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, . | 1.6 | 68 |
| 111 | Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. <i>American Heart Journal</i> , 2017, 185, 74-84. | 1.2 | 68 |
| 112 | Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, E58-67. | 0.7 | 67 |
| 113 | Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517. | 1.2 | 67 |
| 114 | Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Before Left Ventricular Assist Device Surgery. <i>Journal of the American Heart Association</i> , 2018, 7, e010193. | 1.6 | 66 |
| 115 | The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. <i>European Heart Journal</i> , 2014, 35, 1526-1532. | 1.0 | 65 |
| 116 | Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. <i>Circulation</i> , 2022, 145, 392-409. | 1.6 | 65 |
| 117 | A Total of 1,007 Percutaneous Coronary Interventions Without Onsite Cardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1713-1721. | 1.2 | 64 |
| 118 | Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418. | 0.8 | 64 |
| 119 | Comparison of the CHA ₂ DS ₂ -VASc, CHADS ₂ , HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 1549-1556. | 0.7 | 64 |
| 120 | Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States. <i>Circulation: Heart Failure</i> , 2020, 13, e006661. | 1.6 | 64 |
| 121 | Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 604-610. | 0.5 | 63 |
| 122 | Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2025505. | 2.8 | 63 |
| 123 | Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. <i>American Heart Journal</i> , 2014, 168, 160-167. | 1.2 | 62 |
| 124 | Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 27-38. | 1.2 | 62 |
| 125 | Patient factors associated with quality of life in atrial fibrillation. <i>American Heart Journal</i> , 2016, 182, 135-143. | 1.2 | 62 |
| 126 | Impact of Socioeconomic Status, Ethnicity, and Urbanization on Risk Factor Profiles of Cardiovascular Disease in Africa. <i>Circulation</i> , 2016, 133, 1199-1208. | 1.6 | 62 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 62 |
| 128 | Use of Echocardiography in Patients with Hypertrophic Cardiomyopathy: Clinical Implications of Massive Hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 788-795. | 1.2 | 60 |
| 129 | Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?. <i>Lancet, The</i> , 2013, 382, 624-632. | 6.3 | 60 |
| 130 | Aborted myocardial infarction: a new target for reperfusion therapyThe opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 901-904. | 1.0 | 59 |
| 131 | Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. <i>Circulation</i> , 2012, 126, 2115-2124. | 1.6 | 59 |
| 132 | Transcatheter aortic valve implantation in lower-risk patients: what is the perspective?. <i>European Heart Journal</i> , 2018, 39, 658-666. | 1.0 | 59 |
| 133 | Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005358. | 0.9 | 59 |
| 134 | Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, 653-656. | 1.0 | 58 |
| 135 | Incidence of Idiopathic Ventricular Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, . | 2.1 | 57 |
| 136 | From randomized trials to registry studies: translating data into clinical information. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 613-620. | 3.3 | 54 |
| 137 | Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 605-616. | 4.0 | 54 |
| 138 | Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. <i>Heart Rhythm</i> , 2020, 17, 1057-1065. | 0.3 | 54 |
| 139 | Pulmonary artery catheter use in acute myocardial infarction–cardiogenic shock. <i>ESC Heart Failure</i> , 2020, 7, 1234-1245. | 1.4 | 54 |
| 140 | Cardiac cell repair therapy: a clinical perspective. <i>Mayo Clinic Proceedings</i> , 2009, 84, 876-92. | 1.4 | 54 |
| 141 | Do Current Clinical Trials Meet Society’s–Needs?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1615-1628. | 1.2 | 53 |
| 142 | Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003283. | 2.1 | 53 |
| 143 | Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 753-770. | 0.4 | 53 |
| 144 | Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017, 189, 40-47. | 1.2 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2018, 93, 145-154. | 1.4 | 53 |
| 146 | Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock. <i>ESC Heart Failure</i> , 2019, 6, 874-877. | 1.4 | 53 |
| 147 | Heart rate is associated with progression of atrial fibrillation, independent of rhythm. <i>Heart</i> , 2015, 101, 894-899. | 1.2 | 52 |
| 148 | Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2015, 4, . | 1.6 | 52 |
| 149 | Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock. <i>PLoS ONE</i> , 2019, 14, e0222894. | 1.1 | 51 |
| 150 | Regression to the Mean in SYMPPLICITY-AHTN-3. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2016-2025. | 1.2 | 50 |
| 151 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 592-599.e1. | 0.6 | 49 |
| 152 | Is Cardioprotection Salvageable?. <i>Circulation</i> , 2020, 141, 415-417. | 1.6 | 49 |
| 153 | Hemodynamic and Symptomatic Consequences of Ventricular Pacing*. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1982, 5, 903-910. | 0.5 | 48 |
| 154 | A Clinical Perspective on Sudden Cardiac Death. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 177. | 1.3 | 48 |
| 155 | Ten-year trends, predictors and outcomes of mechanical circulatory support in percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock. <i>EuroIntervention</i> , 2021, 16, e1254-e1261. | 1.4 | 48 |
| 156 | Defining Gene Transfer Before Expecting Gene Therapy. <i>Circulation</i> , 2002, 106, 631-636. | 1.6 | 47 |
| 157 | Selection of the optimal reperfusion strategy for STEMI: does time matter?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 761-763. | 1.0 | 46 |
| 158 | Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy. <i>Congenital Heart Disease</i> , 2015, 10, E139-E145. | 0.0 | 46 |
| 159 | Revascularization in Patients With Severe Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2874-2887. | 1.2 | 45 |
| 160 | Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 355-363. | 1.3 | 45 |
| 161 | Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 170-180. | 1.3 | 44 |
| 162 | Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves. <i>Circulation</i> , 2017, 135, 714-716. | 1.6 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1824-1833. | 1.1 | 42 |
| 164 | Facilitated angioplasty: paradise lost. <i>Lancet, The</i> , 2006, 367, 543-546. | 6.3 | 40 |
| 165 | Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2032-2039. | 1.0 | 40 |
| 166 | Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. <i>American Heart Journal</i> , 2016, 171, 40-47. | 1.2 | 40 |
| 167 | Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010300. | 1.4 | 39 |
| 168 | Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 American Journal of Cardiology, 2014, 114, 9-16. | 0.7 | 38 |
| 169 | Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016, 202, 589-594. | 0.8 | 38 |
| 170 | Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378. | 1.5 | 37 |
| 171 | Risk stratification for stroke in atrial fibrillation: a critique. <i>European Heart Journal</i> , 2019, 40, 1294-1302. | 1.0 | 37 |
| 172 | Burden of Arrhythmias in Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2020, 125, 1774-1781. | 0.7 | 37 |
| 173 | Sex and Gender Disparities in the Management and Outcomes of Acute Myocardial Infarction and Cardiogenic Shock in Older Adults. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1916-1927. | 1.4 | 36 |
| 174 | Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 625-632.e1. | 0.6 | 34 |
| 175 | Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 661. | 3.8 | 33 |
| 176 | Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 221-229. | 1.3 | 33 |
| 177 | Rationale and design of REVEAL AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. <i>American Heart Journal</i> , 2014, 167, 22-27. | 1.2 | 32 |
| 178 | The rise, fall, and possible resurrection of renal denervation. <i>Nature Reviews Cardiology</i> , 2016, 13, 238-244. | 6.1 | 32 |
| 179 | Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. <i>American Heart Journal</i> , 2013, 165, 123-132. | 1.2 | 31 |
| 180 | The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. <i>Transactions of the American Clinical and Climatological Association</i> , 2004, 115, 149-59; discussion 159-60. | 0.9 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015, 4, . | 1.6 | 29 |
| 182 | New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309. | 1.4 | 29 |
| 183 | The Natural History of Nonobstructive Hypertrophic Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2016, 91, 279-287. | 1.4 | 28 |
| 184 | Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw058. | 1.8 | 27 |
| 185 | Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 144, 52-59. | 0.7 | 27 |
| 186 | Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls. <i>European Heart Journal</i> , 2007, 28, 1545-1553. | 1.0 | 26 |
| 187 | Modern Management of ST-Segment Elevation Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2020, 45, 100393. | 1.1 | 26 |
| 188 | Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 449-456. | 0.6 | 25 |
| 189 | B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 469-478. | 1.6 | 25 |
| 190 | Association of New-Onset Atrial Fibrillation After Noncardiac Surgery With Subsequent Stroke and Transient Ischemic Attack. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 871. | 3.8 | 25 |
| 191 | Weekend Effect in the Management and Outcomes of Acute Myocardial Infarction in the United States, 2000-2016. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 362-372. | 1.2 | 25 |
| 192 | Late Health Status of Patients Undergoing Myectomy for Obstructive Hypertrophic Cardiomyopathy. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1867-1875. | 0.7 | 25 |
| 193 | Idiopathic Ventricular Fibrillation in Out-of-Hospital Cardiac Arrest Survivors. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1405-1412. | 0.5 | 24 |
| 194 | Association Between Stress Testing—Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1345. | 2.6 | 24 |
| 195 | Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020, 141, 10-20. | 1.6 | 24 |
| 196 | Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2016, 175, 28-35. | 1.2 | 23 |
| 197 | Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. <i>ESC Heart Failure</i> , 2020, 7, 3345-3354. | 1.4 | 23 |
| 198 | B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. <i>Heart</i> , 2019, 105, heartjnl-2018-313642. | 1.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. <i>American Heart Journal</i> , 2020, 223, 65-71. | 1.2 | 22 |
| 200 | Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e200107. | 2.8 | 22 |
| 201 | Cell therapy for cardiovascular disease: what cells, what diseases and for whom?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 37-43. | 3.3 | 21 |
| 202 | Atrial Fibrillation and Stroke Prevention in Aging Patients. <i>Circulation</i> , 2014, 130, 129-131. | 1.6 | 21 |
| 203 | Revascularization in stable coronary disease: evidence and uncertainties. <i>Nature Reviews Cardiology</i> , 2018, 15, 408-419. | 6.1 | 21 |
| 204 | Sex Differences in Long-Term Cause-Specific Mortality After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006062. | 1.4 | 21 |
| 205 | Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. <i>American Heart Journal</i> , 2021, 239, 73-79. | 1.2 | 21 |
| 206 | Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273. | 1.0 | 20 |
| 207 | Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 20 |
| 208 | Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease. <i>Circulation</i> , 2017, 135, 819-821. | 1.6 | 19 |
| 209 | Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019, 105, 235-242. | 1.2 | 19 |
| 210 | Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. <i>American Heart Journal</i> , 2008, 155, 829-840. | 1.2 | 18 |
| 211 | Cardioversion and subsequent quality of life and natural history of atrial fibrillation. <i>American Heart Journal</i> , 2017, 185, 59-66. | 1.2 | 18 |
| 212 | Prognostic Implications of Significant Isolated Tricuspid Regurgitation in Patients With Atrial Fibrillation Without Left-Sided Heart Disease or Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2020, 135, 84-90. | 0.7 | 18 |
| 213 | Gaps in Evidence for Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2021, 143, 101-103. | 1.6 | 18 |
| 214 | Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 962-970. | 0.7 | 17 |
| 215 | Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network). <i>American Journal of Cardiology</i> , 2016, 117, 1904-1910. | 0.7 | 17 |
| 216 | Complications from percutaneous-left ventricular assist devices versus intra-aortic balloon pump in acute myocardial infarction-cardiogenic shock. <i>PLoS ONE</i> , 2020, 15, e0238046. | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008688. | 2.1 | 17 |
| 218 | Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, . | 1.6 | 16 |
| 219 | Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 263-272. | 1.8 | 16 |
| 220 | Impact of Diabetes Mellitus on Stroke and Survival in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 33-39. | 0.7 | 16 |
| 221 | Epidemiological Trends in the Timing of In-Hospital Death in Acute Myocardial Infarction-Cardiogenic Shock in the United States. <i>Journal of Clinical Medicine</i> , 2020, 9, 2094. | 1.0 | 15 |
| 222 | Cardiac cell-repair therapy: clinical issues. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, S105-S109. | 3.3 | 14 |
| 223 | Modern Management of Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2012, 37, 237-310. | 1.1 | 14 |
| 224 | Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. <i>European Journal of Heart Failure</i> , 2017, 19, 457-465. | 2.9 | 14 |
| 225 | Influence of seasons on the management and outcomes acute myocardial infarction: An 18-year US study. <i>Clinical Cardiology</i> , 2020, 43, 1175-1185. | 0.7 | 14 |
| 226 | Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295. | 1.9 | 14 |
| 227 | Left ventricular remodelling after ST-segment elevation myocardial infarction: sex differences and prognosis. <i>ESC Heart Failure</i> , 2020, 7, 474-481. | 1.4 | 14 |
| 228 | Comparative effectiveness of oral anticoagulants in everyday practice. <i>Heart</i> , 2021, 107, 962-970. | 1.2 | 14 |
| 229 | Anticoagulation in Atrial Fibrillation – Current Concepts. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 100. | 1.3 | 13 |
| 230 | Prediction of Cardiac and Noncardiac Mortality After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002121. | 1.4 | 13 |
| 231 | Emboic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1677-1683. | 0.7 | 13 |
| 232 | Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 345-352. | 1.0 | 13 |
| 233 | Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2020, 226, 85-93. | 1.2 | 13 |
| 234 | Utilization and procedural adverse outcomes associated with Watchman device implantation. <i>Europace</i> , 2021, 23, 247-253. | 0.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. <i>ESC Heart Failure</i> , 2021, 8, 2306-2309. | 1.4 | 13 |
| 236 | Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent Transesophageal-Guided Electrical Cardioversion for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 121, 1540-1547. | 0.7 | 12 |
| 237 | Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. <i>Journal of the American Heart Association</i> , 2018, 7, . | 1.6 | 12 |
| 238 | Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. <i>American Heart Journal</i> , 2020, 219, 128-136. | 1.2 | 12 |
| 239 | Transcatheter Aortic Valve Replacement in Low-Risk, Young Patients. <i>Circulation</i> , 2020, 142, 1317-1319. | 1.6 | 12 |
| 240 | Fabry Disease With Resting Outflow Obstruction Masquerading as Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2014, 63, e43. | 1.2 | 11 |
| 241 | Atrial Fibrillation Pathophysiology and Prognosis. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, . | 1.3 | 11 |
| 242 | International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 27-34. | 1.0 | 11 |
| 243 | Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. <i>European Heart Journal</i> , 2020, 41, 1764-1774. | 1.0 | 11 |
| 244 | Myocardial contraction fraction by echocardiography and mortality in cardiac intensive care unit patients. <i>International Journal of Cardiology</i> , 2021, 344, 230-239. | 0.8 | 11 |
| 245 | Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. <i>American Heart Journal</i> , 2019, 213, 81-90. | 1.2 | 10 |
| 246 | Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 | 0.7 | 10 |
| 247 | Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 82-92. | 0.4 | 10 |
| 248 | The role of beta-receptor and calcium-entry-blocking agents in acute myocardial infarction in the thrombolytic era: Can the results of thrombolytic reperfusion be enhanced?. <i>Cardiovascular Drugs and Therapy</i> , 1988, 2, 601-607. | 1.3 | 9 |
| 249 | Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study. <i>Clinical Cardiology</i> , 2017, 40, 982-987. | 0.7 | 9 |
| 250 | Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 435-439. | 1.0 | 9 |
| 251 | In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 511-520. | 1.2 | 9 |
| 252 | Initial and Early Follow-up Assessment of the Clinical Efficacy of a Multiparameter-Programmable Pulse Generator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1981, 4, 417-431. | 0.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | The hypertrophic cardiomyopathy paradox: better with age. <i>European Heart Journal</i> , 2019, 40, 994-996. | 1.0 | 8 |
| 254 | Stroke prevention in atrial fibrillation: Closing the gap. <i>American Heart Journal</i> , 2019, 210, 29-38. | 1.2 | 8 |
| 255 | Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. <i>American Heart Journal</i> , 2020, 219, 21-30. | 1.2 | 8 |
| 256 | New Therapies for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2009, 120, 1024-1026. | 1.6 | 7 |
| 257 | Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 100-109. | 1.2 | 7 |
| 258 | Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471. | 0.9 | 7 |
| 259 | Stem Cells in Cardiovascular Diseases: 30,000-Foot View. <i>Cells</i> , 2021, 10, 600. | 1.8 | 7 |
| 260 | Fibrinolysis vs. primary percutaneous coronary intervention for ST-segment elevation myocardial infarction cardiogenic shock. <i>ESC Heart Failure</i> , 2021, 8, 2025-2035. | 1.4 | 7 |
| 261 | Prognosis following acute coronary syndromes according to prior coronary artery bypass grafting: Meta-analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 518-527. | 0.4 | 6 |
| 262 | Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016, 134, 1122-1124. | 1.6 | 6 |
| 263 | Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. <i>Clinical Cardiology</i> , 2016, 39, 119-125. | 0.7 | 6 |
| 264 | Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials. <i>Heart Rhythm</i> , 2017, 14, 1839-1848. | 0.3 | 6 |
| 265 | Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Prior Cerebrovascular Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2441-2450. | 1.1 | 6 |
| 266 | Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?. <i>American Heart Journal</i> , 2019, 209, 54-62. | 1.2 | 6 |
| 267 | Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007775. | 2.1 | 6 |
| 268 | Use of Artificial Intelligence Tools Across Different Clinical Settings. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008153. | 0.9 | 6 |
| 269 | Pericardial Disease: An Evidence-Based Approach to Diagnosis and Treatment. , 0, , 735-748. | | 6 |
| 270 | Functional classification of left ventricular remodelling: prognostic relevance in myocardial infarction. <i>ESC Heart Failure</i> , 2022, 9, 912-924. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24. | 1.2 | 6 |
| 272 | Artificial Intelligence-Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. <i>Mayo Clinic Proceedings</i> , 2022, 97, 871-880. | 1.4 | 6 |
| 273 | Pharmacological Facilitation of Coronary Intervention in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1292-1294. | 1.1 | 5 |
| 274 | Timing of intervention and outcome in non-ST-elevation acute coronary syndromes: There is risk on both sides of the curve. <i>International Journal of Cardiology</i> , 2014, 177, 23-24. | 0.8 | 5 |
| 275 | Tratamiento de la miocardiopatía hipertrófica sintomática: ¿pastillas, alcohol o bisturí?. <i>Revista Española De Cardiología</i> , 2014, 67, 341-344. | 0.6 | 5 |
| 276 | Repetition rescues regenerative reserve. <i>European Heart Journal</i> , 2016, 37, 1667-1670. | 1.0 | 5 |
| 277 | Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. <i>Circulation</i> , 2018, 137, 2427-2429. | 1.6 | 5 |
| 278 | Management and outcomes of uncomplicated ST-segment elevation myocardial infarction patients transferred after fibrinolytic therapy. <i>International Journal of Cardiology</i> , 2020, 321, 54-60. | 0.8 | 5 |
| 279 | Association of Autoimmune Vasculitis and Incident Atrial Fibrillation: A Population-Based Case-Control Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015977. | 1.6 | 5 |
| 280 | Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561. | 1.0 | 5 |
| 281 | Psychosocial Factors in the Primary and Secondary Prevention of Coronary Heart Disease: An Updated Systematic Review of Prospective Cohort Studies. , 0, , 181-218. | | 5 |
| 282 | Angina in Revascularization of Ischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2101-2103. | 1.2 | 4 |
| 283 | Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). <i>American Journal of Cardiology</i> , 2019, 124, 864-870. | 0.7 | 4 |
| 284 | Relationship Between Anemia and Sudden Cardiac Death in Patients With Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2020, 136, 107-114. | 0.7 | 4 |
| 285 | Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. <i>American Journal of Cardiology</i> , 2020, 127, 16-24. | 0.7 | 4 |
| 286 | Defining the Proper SYNTAX for Long-Term Benefit of Myocardial Revascularization With Optimal Medical Therapy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 39-41. | 1.2 | 4 |
| 287 | Temporal Trends, Management and Outcomes of Acute Myocardial Infarction with Concomitant Respiratory Infections. <i>American Journal of Cardiology</i> , 2021, 150, 1-7. | 0.7 | 4 |
| 288 | Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008991. | 1.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | A Critical Appraisal of the Cardiovascular History and Physical Examination. , 0 , 14-23. | | 4 |
| 290 | The Value of Redundancy in Chronic Bipolar Pacemaker Electrode Systems. PACE - Pacing and Clinical Electrophysiology, 1980, 3, 436-439. | 0.5 | 3 |
| 291 | Myectomy Versus Alcohol Septal Ablation. JACC: Cardiovascular Interventions, 2014, 7, 1235-1236. | 1.1 | 3 |
| 292 | Management of Symptomatic Hypertrophic Cardiomyopathy: Pills, Alcohol, or the Scalpel?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 341-344. | 0.4 | 3 |
| 293 | Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154. | 1.2 | 3 |
| 294 | Incidence and Prognostic Impact of Atrial Fibrillation After Discharge Following Revascularization for Significant Left Main Coronary Artery Narrowing. American Journal of Cardiology, 2020, 125, 500-506. | 0.7 | 3 |
| 295 | Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart, 2021, 107, 642-649. | 1.2 | 3 |
| 296 | Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. American Journal of Cardiology, 2021, 145, 64-68. | 0.7 | 3 |
| 297 | To stent or not to stent? Treating angina after ISCHEMIAâ€™introduction. European Heart Journal, 2021, 42, 1387-1400. | 1.0 | 3 |
| 298 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0 , 837-838. | | 3 |
| 299 | Nonobstructive Hypertrophic Cardiomyopathy in a Patient With Mitral Prosthesis. Annals of Thoracic Surgery, 2021, 111, e429-e432. | 0.7 | 2 |
| 300 | Systolic-to-diastolic myocardial volume ratio as a novel imaging marker of cardiomyopathy. International Journal of Cardiology, 2021, 322, 272-277. | 0.8 | 2 |
| 301 | Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. Diabetology and Metabolic Syndrome, 2021, 13, 17. | 1.2 | 2 |
| 302 | Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0 , 397-425. | | 2 |
| 303 | Restenosis: Etiologies and Prevention. , 0 , 371-394. | | 2 |
| 304 | The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. Contemporary Clinical Trials, 2022, 115, 106732. | 0.8 | 2 |
| 305 | Tobacco and Cardiovascular Disease: Achieving Smoking Cessation. , 0 , 114-120. | | 2 |
| 306 | Indications for Surgery in Aortic Valve Disease. , 0 , 767-781. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Diagnosis and Management of Infective Endocarditis. , 0 , 817-831. | | 2 |
| 308 | Antithrombotic Therapy after Heart Valve Replacement. , 0 , 832-836. | | 2 |
| 309 | Do implantable cardioverter defibrillators lower mortality risk in patients with cardiomyopathy?. Nature Clinical Practice Cardiovascular Medicine, 2004, 1, 16-17. | 3.3 | 1 |
| 310 | Usefulness of Discharge Resting Heart Rate to Predict Adverse Cardiovascular Outcomes in Patients With Left Main Coronary Artery Disease Revascularized With Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting (from the EXCEL Trial). American Journal of Cardiology, 2020, 125, 169-175. | 0.7 | 1 |
| 311 | Secondary prevention after coronary artery bypass grafting saves lives: a golden opportunity often wasted. European Heart Journal, 2020, 41, 1662-1664. | 1.0 | 1 |
| 312 | Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). American Journal of Cardiology, 2020, 132, 66-71. | 0.7 | 1 |
| 313 | To stent or not to stent? Treating angina after ISCHEMIA—the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease. European Heart Journal, 2021, 42, 1389-1393. | 1.0 | 1 |
| 314 | Blood Pressure and Cardiovascular Disease. , 0 , 146-160. | | 1 |
| 315 | The Fetal Origins of Coronary Heart Disease. , 0 , 279-286. | | 1 |
| 316 | Management of Overt Heart Failure. , 0 , 659-680. | | 1 |
| 317 | Which Therapy for Which Condition?. , 2009 , 388-458. | | 1 |
| 318 | Risk of left atrial appendage thrombus and stroke in patients with atrial fibrillation and mitral regurgitation. Heart, 2022, 108, 29-36. | 1.2 | 1 |
| 319 | Prognostic Relevance of Right Ventricular Remodeling after ST-Segment Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2022, 170, 1-9. | 0.7 | 1 |
| 320 | Personalizing Choice of CABG vs PCI for Multivessel Disease. Journal of the American College of Cardiology, 2022, 79, 1474-1476. | 1.2 | 1 |
| 321 | Tobacco: Global Burden and Community Solutions. , 0 , 103-113. | | 1 |
| 322 | Ethnicity and Cardiovascular Disease. , 0 , 259-278. | | 1 |
| 323 | Anti-Ischemic Drugs. , 0 , 329-338. | | 1 |
| 324 | Prevention and Treatment of Life-Threatening Ventricular Arrhythmia and Sudden Death. , 0 , 577-586. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Prevention of Congestive Heart Failure and Treatment of Asymptomatic Left Ventricular Dysfunction. , 0, , 643-658. | | 1 |
| 326 | Finding Current Best Evidence to Practice Evidence-Based Cardiology. , 0, , 40-45. | | 1 |
| 327 | Rheumatic Heart Disease: Prevention and Acute Treatment. , 0, , 751-757. | | 1 |
| 328 | Assessing and Changing Cardiovascular Clinical Practices. , 0, , 71-88. | | 1 |
| 329 | Global Perspective on Cardiovascular Disease. , 0, , 91-102. | | 1 |
| 330 | Which therapy for which condition?. , 2013, , 463-541. | | 1 |
| 331 | Programmed Ventricular Stimulation During Variant Angina: Report of a Case. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1878-1883. | 0.5 | 0 |
| 332 | Is facilitated percutaneous coronary intervention superior to primary percutaneous coronary intervention?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 356-357. | 3.3 | 0 |
| 333 | Response to Letter Regarding Article, "Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy". Circulation, 2009, 119, . | 1.6 | 0 |
| 334 | Antithrombotic Therapy for the Prevention of Reinfarction After Reperfusion Therapy: The Price of Success. Revista Espanola De Cardiologia (English Ed), 2009, 62, 474-478. | 0.4 | 0 |
| 335 | Translation of regenerative technologies into clinical paradigms. Nature Reviews Cardiology, 2014, 11, 554-554. | 6.1 | 0 |
| 336 | Cardiopulmonary Limitation in Hypertrophic Cardiomyopathy. JACC: Heart Failure, 2015, 3, 419-421. | 1.9 | 0 |
| 337 | Are Zebras Simply Striped Horses?. Circulation, 2016, 133, 434-441. | 1.6 | 0 |
| 338 | Response by Vaidya et al to Letter Regarding Article, "Burden of Arrhythmia in Pregnancy". Circulation, 2017, 136, 244-245. | 1.6 | 0 |
| 339 | Arrhythmia Endpoints in Interventional Cardiovascular Trials: A Missed Opportunity?. Structural Heart, 2019, 3, 20-23. | 0.2 | 0 |
| 340 | Prognostic significance of patent foramen ovale in anticoagulated patients with atrial fibrillation. Open Heart, 2020, 7, e001229. | 0.9 | 0 |
| 341 | Professor Lionel H. Opie 6th May 1933â€"20th February 2020. European Heart Journal, 2020, 41, 1620-1621. | 1.0 | 0 |
| 342 | Improving Communication of Incidental Imaging Findings. Mayo Clinic Proceedings, 2021, 96, 2753-2756. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Postoperative Atrial Fibrillation After Noncardiac Surgery and Stroke—Reply. JAMA - Journal of the American Medical Association, 2021, 325, 187. | 3.8 | 0 |
| 344 | Abstract 371: Prevalence and Spectrum of Thin Filament Mutations in 1025 Patients with Hypertrophic Cardiomyopathy. Circulation, 2007, 116, . | 1.6 | 0 |
| 345 | Abstract 3393: Expression Patterns of the Cardiac Myofilament Proteins- Analysis of Surgical Myectomy Tissue from Patients with Sarcomeric Hypertrophic Cardiomyopathy. Circulation, 2007, 116, . | 1.6 | 0 |
| 346 | Abstract 3521: Relationship Between Time from Symptom Onset to Hospital Presentation and Treatment with and Timeliness of Reperfusion Therapy for Patients with ST-Elevation Myocardial Infarction. Circulation, 2007, 116, . | 1.6 | 0 |
| 347 | Inherited Arrhythmias — Where do we Stand?. Arrhythmia and Electrophysiology Review, 2014, 3, 80. | 1.3 | 0 |
| 348 | Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation, 2014, 130, . | 1.6 | 0 |
| 349 | Early Repolarisation Syndrome — New Concepts. Arrhythmia and Electrophysiology Review, 2015, 4, 169. | 1.3 | 0 |
| 350 | Abstract 152: Persistence of Warfarin versus Dabigatran Therapy in Patients with Atrial Fibrillation: Results from the ORBIT AF Registry. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, . | 0.9 | 0 |
| 351 | The PEACE trial: ACE inhibitors and coronary artery disease. Reviews in Cardiovascular Medicine, 2005, 6, 54-9. | 0.5 | 0 |
| 352 | What is Evidence-Based Cardiology?. , 0, , 3-13. | | 0 |
| 353 | Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease. , 0, , 130-145. | | 0 |
| 354 | Glucose Abnormalities and Cardiovascular Disease:—Dysglycemia—as an Emerging Cardiovascular Risk Factor. , 0, , 161-169. | | 0 |
| 355 | Physical Activity and Exercise in Cardiovascular Disease Prevention and Rehabilitation. , 0, , 170-180. | | 0 |
| 356 | Emerging Approaches in Cardiovascular Prevention. , 0, , 219-230. | | 0 |
| 357 | Postmenopausal Hormone Therapy and Cardiovascular Disease. , 0, , 244-258. | | 0 |
| 358 | Molecular Genetics of Cardiovascular Disorders. , 0, , 287-299. | | 0 |
| 359 | Cost Effectiveness of Prevention of Cardiovascular Disease. , 0, , 300-308. | | 0 |
| 360 | Diet and Cardiovascular Disease. , 0, , 309-325. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 361 | Adjunctive Medical Therapy in Percutaneous Coronary Intervention. , 0 , 360-370. | | 0 |
| 362 | Obtaining Incremental Information from Diagnostic Tests. , 0 , 24-33. | | 0 |
| 363 | Fibrinolytic Therapy. , 0 , 426-443. | | 0 |
| 364 | Mechanical Reperfusion Strategies in Patients Presenting with Acute Myocardial Infarction. , 0 , 444-455. | | 0 |
| 365 | Adjunctive Antithrombotic Therapy for St-Elevation Acute Myocardial Infarction. , 0 , 456-476. | | 0 |
| 366 | Pain Relief, General Management, and Other Adjunctive Treatments. , 0 , 477-487. | | 0 |
| 367 | An Integrated Approach to the Management of Patients After the Early Phase of the Acute Coronary Syndromes. , 0 , 507-516. | | 0 |
| 368 | Atrial Fibrillation: Antiarrhythmic Therapy. , 0 , 519-547. | | 0 |
| 369 | Atrial Fibrillation: Antithrombotic Therapy. , 0 , 548-555. | | 0 |
| 370 | Atrial Fibrillation: Non-Pharmacologic Therapies. , 0 , 556-566. | | 0 |
| 371 | Clinical Trials and Meta-Analysis. , 0 , 34-39. | | 0 |
| 372 | Impact of Pacemakers: When and What Kind?. , 0 , 587-618. | | 0 |
| 373 | Acute Myocarditis and Dilated Cardiomyopathy. , 0 , 681-702. | | 0 |
| 374 | Other Cardiomyopathies. , 0 , 718-732. | | 0 |
| 375 | Mitral Valve Disease: Indications for Surgery. , 0 , 758-766. | | 0 |
| 376 | Balloon Valvuloplasty: Aortic Valve. , 0 , 782-795. | | 0 |
| 377 | Balloon Valvuloplasty: Mitral Valve. , 0 , 796-808. | | 0 |
| 378 | Valve Repair and Choice of Valves. , 0 , 809-816. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|----|-----------|
| 379 | Treatment of Patients with Stroke. , 0 , 839-852. | | 0 |
| 380 | Understanding Concepts Related to Health Economics. , 0 , 46-55. | | 0 |
| 381 | Heart Disease and Pregnancy. , 0 , 853-863. | | 0 |
| 382 | Venous Thromboembolic Disease. , 0 , 864-876. | | 0 |
| 383 | Clinical Applications of External Evidence. , 0 , 889-891. | | 0 |
| 384 | Stable Angina: Choice of PCIv CABGv Drugs. , 0 , 892-895. | | 0 |
| 385 | Postmyocardial Infarction: Preventive Measures. , 0 , 906-908. | | 0 |
| 386 | Metabolic Risk and Secondary Prevention of Coronary Disease. , 0 , 909-911. | | 0 |
| 387 | Peripheral Vascular Disease with Suspect Coronary Artery Disease. , 0 , 912-914. | | 0 |
| 388 | Introduction to Decision Analysis. , 0 , 56-70. | | 0 |
| 389 | Ventricular Dysrhythmias: Pharmacologicv Non-Pharmacologic Treatment. , 0 , 925-930. | | 0 |
| 390 | Bradycarrhythmias: Choice of Pacemaker. , 0 , 931-933. | | 0 |
| 391 | Valvular Heart Disease: Timing of Surgery. , 0 , 934-937. | | 0 |
| 392 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0 , 1-2. | | 0 |
| 393 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0 , 887-888. | | 0 |
| 394 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0 , 89-90. | | 0 |
| 395 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0 , 327-328. | | 0 |
| 396 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0 , 395-396. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 397 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 517-518. | | 0 |
| 398 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 575-576. | | 0 |
| 399 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 641-642. | | 0 |
| 400 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 733-734. | | 0 |
| 401 | Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 749-750. | | 0 |